We have previously studied the innate immune response in cases with pure (only Aβ and tau) AD pathology, showing that microglia activation follows the progression of Aβ plaques and NFT, while Aβ pathology or NFT pathology alone were not sufficient to drive a strong microglia response [65]. The gene discussed is MAPT; the disease is Alzheimer disease.